44 research outputs found
The influence of climatic factors on the course of pregnancy in women of the far north
The article describes the influence of climatic and geographic conditions on the course of pregnancy in women of the Tazovsky district in the far North (Yamalo-Nenets). After analyzing the course of pregnancy on individual cards found that the course of pregnancy has a significant effect on the change in photoperiodicity. In the years of high solar activity, the frequency of complications increases in indigenous and alien residents. In this regard, it is necessary to carry out preventive measures to identify and eliminate complications during pregnancy in all residents of the NorthΠ ΡΡΠ°ΡΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΊΠ»ΠΈΠΌΠ°ΡΠΎ-Π³Π΅ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ»ΠΎΠ²ΠΈΠΉ Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Ρ ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΈΡ Π’Π°Π·ΠΎΠ²ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΠΉΠΎΠ½Π° ΠΡΠ°ΠΉΠ½Π΅Π³ΠΎ Π‘Π΅Π²Π΅ΡΠ° (Π―ΠΠΠ). ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΠΏΠΎ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΠΌ ΠΊΠ°ΡΡΠ°ΠΌ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠΎΡΠΎΠΏΠ΅ΡΠΈΠΎΠ΄ΠΈΡΠ½ΠΎΡΡΠΈ. Π Π³ΠΎΠ΄Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΠΎΠ»Π½Π΅ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ°ΡΡΠΎΡΠ° ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π΅Ρ Ρ ΠΊΠΎΡΠ΅Π½Π½ΡΡ
ΠΈ ΠΏΡΠΈΡΠ»ΡΡ
ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΈΡ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΏΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΈ ΡΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Ρ Π²ΡΠ΅Ρ
ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΈΡ Π‘Π΅Π²Π΅Ρ
The influence of climatic factors on the course of pregnancy in women of the far north
The article describes the influence of climatic and geographic conditions on the course of pregnancy in women of the Tazovsky district in the far North (Yamalo-Nenets). After analyzing the course of pregnancy on individual cards found that the course of pregnancy has a significant effect on the change in photoperiodicity. In the years of high solar activity, the frequency of complications increases in indigenous and alien residents. In this regard, it is necessary to carry out preventive measures to identify and eliminate complications during pregnancy in all residents of the NorthΠ ΡΡΠ°ΡΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΊΠ»ΠΈΠΌΠ°ΡΠΎ-Π³Π΅ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ»ΠΎΠ²ΠΈΠΉ Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Ρ ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΈΡ Π’Π°Π·ΠΎΠ²ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΠΉΠΎΠ½Π° ΠΡΠ°ΠΉΠ½Π΅Π³ΠΎ Π‘Π΅Π²Π΅ΡΠ° (Π―ΠΠΠ). ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΠΏΠΎ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΠΌ ΠΊΠ°ΡΡΠ°ΠΌ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠΎΡΠΎΠΏΠ΅ΡΠΈΠΎΠ΄ΠΈΡΠ½ΠΎΡΡΠΈ. Π Π³ΠΎΠ΄Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΠΎΠ»Π½Π΅ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ°ΡΡΠΎΡΠ° ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π΅Ρ Ρ ΠΊΠΎΡΠ΅Π½Π½ΡΡ
ΠΈ ΠΏΡΠΈΡΠ»ΡΡ
ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΈΡ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΏΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΈ ΡΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Ρ Π²ΡΠ΅Ρ
ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΈΡ Π‘Π΅Π²Π΅Ρ
STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA
Interstitial lung disease (ILD) is one of the major causes of death in systemic scleroderma (SSD). Treatment of these patients remains difficult and controversial. Mycophenolate mofetil (MPM) has been in vitro shown to inhibit overproduction of type I collagen and hence may be effective against SSD. Objective: to study the efficiency and safety of MPM therapy in patients with SSD and clinically relevant ILD in an open-label prospective study. Subjects and methods. Ten patients with SSD (7 and 3 with its diffuse and limited forms, respectively) and ILD were given MPM in combination with glucocorticoids (mean daily dose was 10+4 mg). The mean MPM therapy duration was 11.4+1.3 months. The Rodnan total skin thickness score, flexion index, forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), and European Scleroderma Study Group (EScSG) activity index were estimated and a 6-minute walk test (6MWT) was carried out before and after MPM therapy. Results. After therapy, the whole group showed a significant reduction in skin scores from 12.9+9.8 to 5.6+3.2 (p=0.036) and EScSG from 3.9+1.4 to 2.25+1.03 (p=0.015) and an increase in exercise tolerance from 446+155 to 535+78 m (p=0.03) as evidenced by 6MWT. The degree of flexion contractures decreased from 15+21 to 3.7+11.3 mm (p>0.05). FVC (77.8+18.7% versus 73.8+11.3%) and DLCO (45+14.4% versus 42+16.4%) were significantly unchanged. A 10% or more clinically significant fall was noted in FVC and DLCO in 3 and 1 patients, respectively. In the remaining patients, the lung functional test results remained stable. MPM tolerability was satisfactory. All the patients completed their course of treatment. Conclusion. Stabilization of lung function with higher exercise tolerance and significantly reduced skin density allow therapy with MPM in combination with low-dose glucocorticoids to be regarded as an effective and well-tolerated treatment in patients with ILD in the presence of SS
Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠ΅ΠΉ
Objective: to assess the frequency of a reduction in bone mineral density (BMD) and its association with traditional risk factors and clinical parameters in patients with systemic scleroderma (SSD).Patients and methods. The investigation included 330people: 190 patients (median age 55 [41; 61.5] years) with SSD and 140 control individuals (median age 57 [40.5; 66] years without a history of inflammatory rheumatic diseases. The patients were interviewed using a uniform questionnaire; dual-energy X-ray absorptiometry was used to measure BMD in the lumbar spine (Li-iv), femoral neck (FN), entire proximal femur (PF), and distal third of the forearm (DTF). The concentration of 25(OH)D was measured in 155 examinees.Results and discussion. Decreased BMD was found in 69% of patients with SSD and in 58% of controls (p=0.0392), including osteoporosis (OP) in 38 and 31% of cases, respectively. BMD in the Li-iv and FN was significantly lower in the women with SSD than in the control exam-nees, regardless of age. There was a direct correlation between BMD and body mass index (BMi) and an inverse correlation between BMD and the duration of menopause, that of the disease, and cumulative dose of glucocorticoids (GCs). Among the analyzed clinical factors, there was an inverse correlation between Li-iv BMD and erythrocyte sedimentation rate (ESR), between BMD in both femoral areas (FN and PF) and C-reactive protein (CRP). The mean concentration of 25(OH)D was 19.83+11.06 ng/mL in the patients with SSD and 23.29+8.61 ng/mL in the controls; normal vitamin D levels were detected in 9% of the patients with SSD and 24% of the controls (p<0.05).Conclusion. Low BMD was found in 69% of patients with SSD, including in those with OP (38%). Most (91%) patients had vitamin D deficiency. BMD correlated with traditional risk factors: positively with BMi and negatively with age and menopause duration. The clinical factors were found to be association with disease duration and cumulative GC dose.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° ΡΠ°ΡΡΠΎΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠΈ (ΠΠΠ) ΠΈ Π΅Π΅ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠ΅ΠΉ (Π‘Π‘Π).ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 330 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ: 190 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π‘Π (ΠΌΠ΅Π΄ΠΈΠ°Π½Π° Π²ΠΎΠ·ΡΠ°ΡΡΠ° 55 [41; 61,5] Π»Π΅Ρ) ΠΈ 140 Π»ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ Π±Π΅Π· Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅ (ΠΌΠ΅Π΄ΠΈΠ°Π½Π° Π²ΠΎΠ·ΡΠ°ΡΡΠ° 57[40,5; 66] Π»Π΅Ρ). ΠΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ ΠΎΠΏΡΠΎΡΠ΅Π½Ρ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π°Π½ΠΊΠ΅ΡΡ, ΠΠΠ ΠΈΠ·ΠΌΠ΅ΡΡΠ»ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π΄Π²ΡΡΠ½Π΅ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠΉ Π°Π±ΡΠΎΡΠ±-ΡΠΈΠΎΠΌΠ΅ΡΡΠΈΠΈ Π² ΠΏΠΎΡΡΠ½ΠΈΡΠ½ΠΎΠΌ ΠΎΡΠ΄Π΅Π»Π΅ ΠΏΠΎΠ·Π²ΠΎΠ½ΠΎΡΠ½ΠΈΠΊΠ° (Li-rv), ΡΠ΅ΠΉΠΊΠ΅ Π±Π΅Π΄ΡΠ° (Π¨Π), ΠΏΡΠΎΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΌ ΠΎΡΠ΄Π΅Π»Π΅ Π±Π΅Π΄ΡΠ° Π² ΡΠ΅Π»ΠΎΠΌ (ΠΠΠ) ΠΈ Π² ΠΎΠ±Π»Π°ΡΡΠΈ ΡΡΠ΅ΡΠΈ Π΄ΠΈΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΡΠ΄Π΅Π»Π° ΠΏΡΠ΅Π΄ΠΏΠ»Π΅ΡΡΡ (ΠΠΠ). ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ 25(OH)D ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Ρ 155 ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π‘Π½ΠΈΠΆΠ΅Π½Π½Π°Ρ ΠΠΠ Π²ΡΡΠ²Π»Π΅Π½Π° Ρ 69% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π‘Π ΠΈ 58% Π»ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ (Ρ=0,0392), Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ· (ΠΠ) β Ρ 38 ΠΈ 31% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠ΅Π»ΠΈΡΠΈΠ½Π° ΠΠΠ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π‘Π‘Π Π² Li-ivu Π¨Π Π±ΡΠ»Π° Π·Π½Π°ΡΠΈΠΌΠΎ ΠΌΠ΅Π½ΡΡΠ΅, ΡΠ΅ΠΌ Ρ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ, Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΠΎ ΠΎΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ°. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° ΠΏΡΡΠΌΠ°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ Π²Π΅Π»ΠΈΡΠΈΠ½ΠΎΠΉ ΠΠΠ ΠΈ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° (ΠΠΠ’) ΠΈ ΠΎΠ±ΡΠ°ΡΠ½Π°Ρ β Ρ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Ρ, Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΊΡΠΌΡΠ»ΡΡΠΈΠ²Π½ΠΎΠΉ Π΄ΠΎΠ·ΠΎΠΉ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΠΈΠ΄ΠΎΠ² (ΠΠ). Π‘ΡΠ΅Π΄ΠΈ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° ΠΎΠ±ΡΠ°ΡΠ½Π°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ ΠΠΠ Π² Li-vu Π‘ΠΠ; ΠΌΠ΅ΠΆΠ΄Ρ ΠΠΠ Π² ΠΎΠ±Π΅ΠΈΡ
ΠΎΠ±Π»Π°ΡΡΡΡ
ΠΠΠ (Π¨Π ΠΈ ΠΠΠ) ΠΈ Π‘Π Π. Π‘ΡΠ΅Π΄Π½ΡΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ 25(OH)D ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 19,83+11,06Π½Π³/ΠΌΠ» Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π‘Π ΠΈ 23,29+8,61 Π½Π³/ΠΌΠ» Ρ Π»ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ; Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ Ρ 9 ΠΈ 24% ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p<0,05).ΠΡΠ²ΠΎΠ΄Ρ. ΠΠΈΠ·ΠΊΠ°Ρ ΠΠΠ Π²ΡΡΠ²Π»Π΅Π½Π° Ρ 69% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π‘Π, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΠΠ - Ρ 38%. ΠΠ΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ ΠΈ Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΈΠΌΠ΅Π»ΠΈΡΡ Ρ 91% Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΠ΅Π»ΠΈΡΠΈΠ½Π° ΠΠΠ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π»Π° Ρ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ°: ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΠΎ Ρ ΠΠΠ’ ΠΈ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΠΎ Ρ Π²ΠΎΠ·ΡΠ°ΡΡΠΎΠΌ ΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Ρ. Π‘ΡΠ΅Π΄ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° ΡΠ²ΡΠ·Ρ Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΠΊΡΠΌΡΠ»ΡΡΠΈΠ²Π½ΠΎΠΉ Π΄ΠΎΠ·ΠΎΠΉ ΠΠ
ΠΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π΄ΠΈΡΡΡΠ·ΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ Π»Π΅Π³ΠΊΠΈΡ ΠΏΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ Π±Π΅Π· Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ: Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅
The objective of this 5year prospective study was to investigate a clinical role of isolated decrease of DLCO in patients with systemic sclerosis (SS)Β without pulmonary arterial hypertension (PAH).Methods. We selected 48 out of 142 patients with SS: 35 (73%) with limited SS and 13 (27%) withΒ diffuse SS. The average length of the disease was 12.9 Β± 7.9 years. Inclusion criteria were DLCO < 80% pred., forced vital capacity (FVC) β₯ 80%Β pred. and systolic pulmonary artery pressure (PAP) β€ 35 mm Hg according to echocardiographic examination (echoCG). High resolution computed tomography (HRCT), spirometry, DLCO measurement, and echoCG were obtained at baseline and after 4.7 Β± 1 year of follow up. All patientsΒ were treated with standard therapy.Results. CT signs of interstitial lung disease (ILD) were found in 43 (89.6%) patients at baseline and newly developed in 3 other patients during the followup. During the followup, lung CT improved in 5 (10.4%) patients and progressed in 15 (31.3%) patients.Β Over 5 years, FVC did not change significantly (97.6 Β± 10.7% and 100.8 Β± 18.9%; Ρ = 0.15), while DLCO significantly decreased both in limitedΒ and diffuse SS groups (59.8 Β± 13.5% and 56.3 Β± 12%; Ρ = 0.006). Mean PAP values remained within normal range in majority of patients. ClinicallyΒ significant FVC reduction (β₯ 10%) was found in 5 patients; of them, CT signs of ILD at baseline were seen in 3 patients and newly developed during the followup in 2 others. Clinically significant DLCO reduction (β₯ 10%) was documented in 11 (23%) patients, all had CT signs of ILD at baseline, although CT progression during the followup was noted only in six of them. Contemporary deterioration in FVC, DLCO and CT was found in 3 patients.Conclusion. Clinical course of ILD in SS patients with isolated DLCO reduction and without PAH was relatively benign, with respiratoryΒ volumes being preserved within normal range for long time. Comparison of radiological and functional changes in a prospective study has suggested that DLCO is a more sensitive tool to determine ILD progression compared to HRCT. Regular DLCO measurements could be used as a reliable toolΒ for monitoring of ILD associated with SS.ΠΠ½ΡΠ΅ΡΡΡΠΈΡΠΈΠ°Π»ΡΠ½ΠΎΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ Π»Π΅Π³ΠΊΠΈΡ
(ΠΠΠ) ΠΏΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ (Π‘Π‘Π), ΠΊΠ°ΠΊ ΠΏΡΠ°Π²ΠΈΠ»ΠΎ, ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅ΡΡΡ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠ²Π½ΡΠΌΠΈΒ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ, ΠΏΡΠΈ ΡΡΠΎΠΌ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΎΠ±ΡΠ΅ΠΌΠΎΠ² ΠΈ Π΄ΠΈΡΡΡΠ·ΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ Π»Π΅Π³ΠΊΠΈΡ
(DLCO) ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΡΒ ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎ. Π ΡΡΠ΄Π΅ ΡΠ»ΡΡΠ°Π΅Π² ΠΏΡΠΈ ΠΠΠ Π²ΡΡΠ²Π»ΡΠ΅ΡΡΡ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ DLCO, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΠΎΡΡΠ°Π΅ΡΡΡ Π΄ΠΎ ΠΊΠΎΠ½ΡΠ°Β Π½Π΅ΡΡΠ½ΡΠΌ.Π¦Π΅Π»Ρ. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ DLCO Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π‘Π‘Π Π±Π΅Π· Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ (ΠΠΠ)Β Π² 5Π»Π΅ΡΠ½Π΅ΠΌ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ· Π±ΠΎΠ»ΡΠ½ΡΡ
(n = 142), Π½Π°Π±Π»ΡΠ΄Π°Π²ΡΠΈΡ
ΡΡ Π² Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠΌ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΌΒ Π±ΡΠ΄ΠΆΠ΅ΡΠ½ΠΎΠΌ Π½Π°ΡΡΠ½ΠΎΠΌ ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΈ Β«ΠΠ°ΡΡΠ½ΠΎΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΈΠΉ ΠΈΠ½ΡΡΠΈΡΡΡ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌΠ΅Π½ΠΈ Π.Π.ΠΠ°ΡΠΎΠ½ΠΎΠ²ΠΎΠΉΒ», ΠΎΡΠΎΠ±ΡΠ°Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡΒ (n = 48) Ρ Π»ΠΈΠΌΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ β 35 (73 %) ΠΈ Π΄ΠΈΡΡΡΠ·Π½ΠΎΠΉ β 13 (27 %) ΡΠΎΡΠΌΠ°ΠΌΠΈ Π‘Π‘Π (Π΄Π°Π²Π½ΠΎΡΡΡ Π‘Π‘Π β 12,9 Β± 7,9 Π³ΠΎΠ΄Π°; ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ DLCO < 80 %;Β ΡΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΠΆΠΈΠ·Π½Π΅Π½Π½Π°Ρ Π΅ΠΌΠΊΠΎΡΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π€ΠΠΠ) β₯ 80 %Π΄ΠΎΠ»ΠΆ., ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΠΠ ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ ΡΡ
ΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΠΈ (ΠΡ
ΠΎΠΠ); ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ΅Β Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅ Π² Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠΈ (Π‘ΠΠΠ) β€ 35 ΠΌΠΌ ΡΡ. ΡΡ.). ΠΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½Π°Ρ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΡ Π²ΡΡΠΎΠΊΠΎΠ³ΠΎ ΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΈΡ (ΠΠ’ΠΠ ), ΡΠΏΠΈΡΠΎΠΌΠ΅ΡΡΠΈΡ,Β ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ DLCO, ΠΡ
ΠΎΠΠ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈΡΡ ΠΏΡΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠΈ Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ ΡΠ΅ΡΠ΅Π· 4,7 Β± 1,0 Π³ΠΎΠ΄Π°. ΠΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΡΒ ΡΠ΅ΡΠ°ΠΏΠΈΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠΈ Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΠ’ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΠΠΠ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ Ρ 43 (89,6 %) Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈ ΡΠ΅ΡΠ΅Π· 5 Π»Π΅Ρ ΠΏΠΎΡΠ²ΠΈΠ»ΠΈΡΡ Π΅ΡΠ΅Β Ρ 3; ΠΏΡΠΈ ΡΡΠΎΠΌ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΠ’Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° Ρ 5 (10,4 %), ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ β Ρ 15 (31,3 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π€ΠΠΠΒ Π² ΡΡΠ΅Π΄Π½Π΅ΠΌ ΠΏΠΎ Π³ΡΡΠΏΠΏΠ΅ Π·Π½Π°ΡΠΈΠΌΠΎ Π½Π΅ ΠΈΠ·ΠΌΠ΅Π½ΠΈΠ»ΠΈΡΡ (97,6 Β± 10,7 ΠΈ 100,8 Β± 18,9 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ; Ρ = 0,15), DLCO Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠ½ΠΈΠ·ΠΈΠ»Π°ΡΡ (59,8 Β±Β 13,5 ΠΈ 56,3 Β± 12,0 % ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ; Ρ = 0,006). ΠΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π‘ΠΠΠ ΠΎΡΡΠ°Π²Π°Π»ΠΈΡΡ Π² ΠΏΡΠ΅Π΄Π΅Π»Π°Ρ
Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π°Β ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ (β₯ 10 %) ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π€ΠΠΠ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Ρ 5 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΈΠ· Π½ΠΈΡ
Π² 3 ΡΠ»ΡΡΠ°ΡΡ
ΠΠ’ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΠΠΠ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΡΒ ΠΏΡΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠΈ Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, Π² 2 β ΠΏΠΎΡΠ²ΠΈΠ»ΠΈΡΡ Π² Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ DLCO (β₯ 10 %) ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ Ρ 11 (23 %)Β ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π£ Π²ΡΠ΅Ρ
ΠΏΡΠΈ 1ΠΌ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ ΠΠ’ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΠΠΠ, ΠΎΠ΄Π½Π°ΠΊΠΎ ΡΠΎΠ»ΡΠΊΠΎ Π² 6 ΡΠ»ΡΡΠ°ΡΡ
Π² Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ Π½Π°ΡΠ°ΡΡΠ°Π½ΠΈΠ΅Β ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΠΠ. ΠΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π€ΠΠΠ ΠΈ DLCO, ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π²ΡΠ΅Π΅ΡΡ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΠΠ, Π²ΡΡΠ²Π»Π΅Π½ΠΎ Ρ 3 Π±ΠΎΠ»ΡΠ½ΡΡ
.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π’Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΠΠ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π‘Π‘Π Ρ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ DLCO Π±Π΅Π·Β ΠΠΠ Π±ΡΠ»ΠΎ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ Ρ ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ΠΌ Π»Π΅Π³ΠΎΡΠ½ΡΡ
ΠΎΠ±ΡΠ΅ΠΌΠΎΠ² Π² ΠΏΡΠ΅Π΄Π΅Π»Π°Ρ
Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎΒ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ. ΠΡΠΈ ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠΈ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΈ Π»Π΅Π³ΠΎΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ² Π² ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΌ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ, ΡΡΠΎ Π² ΠΎΡΡΠ°ΠΆΠ΅Π½ΠΈΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΠΠ DLCO ΡΠ²Π»ΡΠ΅ΡΡΡ Π±ΠΎΠ»Π΅Π΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠ΅ΡΡΠΎΠΌ, ΡΠ΅ΠΌ ΠΠ’ΠΠ . Π Π΅Π³ΡΠ»ΡΡΠ½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ DLCO ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡΒ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΠΌ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠΎΠΌ Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Π‘Π‘Π ΠΏΡΠΈ ΠΠΠ
Electronic properties and phase transitions in low-dimensional semiconductors
We present the first review of the current state of the literature on
electronic properties and phase transitions in TlX and TlMX2 (M = Ga, In; X =
Se, S, Te) compounds. These chalcogenides belong to a family of the
low-dimensional semiconductors possessing chain or layered structure. They are
of significant interest because of their highly anisotropic properties, semi-
and photoconductivity, non-linear effects in their I-V characteristics
(including a region of negative differential resistance), switching and memory
effects, second harmonic optical generation, relaxor behavior and potential
applications for optoelectronic devices. We review the crystal structure of TlX
and TlMX2 compounds, their transport properties under ambient conditions,
experimental and theoretical studies of the electronic structure, transport
properties and semiconductor-metal phase transitions under high pressure, and
sequences of temperature-induced structural phase transitions with intermediate
incommensurate states. Electronic nature of the ferroelectric phase transitions
in the above-mentioned compounds, as well as relaxor behavior, nanodomains and
possible occurrence of quantum dots in doped and irradiated crystals is
discussed.Comment: 70 pages, 38 figure
Sildenafil in the treatment of Raynaudβs syndrome
Π‘ΠΈΠ½Π΄ΡΠΎΠΌ Π Π΅ΠΉΠ½ΠΎ (Π‘Π ) ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΠ΅Π·ΠΌΠ΅ΡΠ½ΠΎΠΉ Π²Π°Π·ΠΎΡΠΏΠ°ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠ΅ΠΉ Π½Π° Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Ρ
ΠΎΠ»ΠΎΠ΄Π° ΠΈΠ»ΠΈ ΡΠΌΠΎΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠ΅. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌ ΠΏΡΠΎΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ΅Π·ΠΊΠΎ ΠΎΡΠ΅ΡΡΠ΅Π½Π½ΡΠΌΠΈ ΡΡΠ°ΡΡΠΊΠ°ΠΌΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΎΠΊΡΠ°ΡΠΊΠΈ ΠΊΠΎΠΆΠΈ (ΠΏΠΎΠ±Π΅Π»Π΅Π½ΠΈΠ΅/ΠΏΠΎΡΠΈΠ½Π΅Π½ΠΈΠ΅) ΠΏΠ°Π»ΡΡΠ΅Π² ΠΊΠΈΡΡΠ΅ΠΉ ΠΈ ΡΡΠΎΠΏ. Π ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ Π² ΡΡΡΠ°Π½Π°Ρ
Ρ Ρ
ΠΎΠ»ΠΎΠ΄Π½ΡΠΌ ΠΊΠ»ΠΈΠΌΠ°ΡΠΎΠΌ, ΠΎΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ Π‘Π , ΠΊΠΎΡΠΎΡΠ°Ρ Π΄ΠΎΡΡΠΈΠ³Π°Π΅Ρ 3-5% [1]. Π Π°Π·Π»ΠΈΡΠ°ΡΡ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΡΠΉ, ΠΈΠ»ΠΈ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ, ΠΈ Π²ΡΠΎΡΠΈΡΠ½ΡΠΉ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ, Π‘Π . ΠΠ΅ΡΠ²ΠΈΡΠ½ΡΠΉ Π‘Π Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ ΡΠΈΠΌΠΌΠ΅ΡΡΠΈΡΠ½ΠΎΡΡΡΡ Π°ΡΠ°ΠΊ Π²Π°Π·ΠΎΡΠΏΠ°Π·ΠΌΠ°, ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΠΈΠ·ΡΡΠ·Π²Π»Π΅Π½ΠΈΠΉ ΠΈ Π½Π΅ΠΊΡΠΎΠ·ΠΎΠ² ΡΠΊΠ°Π½Π΅ΠΉ, ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² Π΄ΡΡΠ³ΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΠ°ΠΏΠΈΠ»Π»ΡΡΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΉ, ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ ΡΠ΅ΡΡΠ° Π½Π° Π°Π½ΡΠΈΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΠ΅ Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΈ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ Π‘ΠΠ [2]. ΠΡΠΈ Π²ΡΠΎΡΠΈΡΠ½ΠΎΠΌ Π‘Π Π°ΡΠ°ΠΊΠΈ Π²Π°Π·ΠΎΡΠΏΠ°Π·ΠΌΠ° ΠΎΠ±ΡΡΠ½ΠΎ Π±ΡΠ²Π°ΡΡ Π±ΠΎΠ»Π΅Π΅ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΡΠΌΠΈ, ΠΌΠΎΠ³ΡΡ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°ΡΡΡΡ ΡΠΈΠ»ΡΠ½ΠΎΠΉ Π±ΠΎΠ»ΡΡ, ΡΠ°ΡΡΠΎ ΡΠ°Π·Π²ΠΈΠ²Π°ΡΡΡΡ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠ΅ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΡΠΊΠ°Π½Π΅ΠΉ Π² Π²ΠΈΠ΄Π΅ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΈΡΡΡΡΠΈΡ
Π΄ΠΈΠ³ΠΈΡΠ°Π»ΡΠ½ΡΡ
ΠΈ ΠΈΠ½ΡΡ
ΠΊΠΎΠΆΠ½ΡΡ
ΠΈΠ·ΡΡΠ·Π²Π»Π΅Π½ΠΈΠΉ, Π³Π°Π½Π³ΡΠ΅Π½Ρ ΡΠ°Π»Π°Π½Π³ ΠΏΠ°Π»ΡΡΠ΅Π² ΠΊΠΈΡΡΠ΅ΠΉ ΠΈ ΡΡΠΎΠΏ [3]
Intravenous immunoglobulin for intensive therapy of fibrosing alveolitis in a patient TOC \o "1-5" \h \z with systemic sclerosis
A case of quite successful administration of intravenous immunoglobulin as a component of programmed intensive therapy in a patient with systemic sclerosis and signs of fibrosing alveolitis
SYSTEMIC SCLEROSIS AND OSTEOPOROSIS
Systemic sclerosis is an autoimmune inflammatory disease of connective tissue with multi-syndrome clinical manifestations. Skeletal damage is considered to be one of significant contributors to the quality of life of these patients. The purpose of this review was to assess the prevalence of osteoporosis and associated fractures in systemic sclerosis. We performed a search in Medline database by the following key words: βsystemic sclerosisβ, βbone mineral densityβ and βosteoporosisβ. From 118 publications we selected for further analysis 18 papers which contained comparisons of bone mineral density in patients with systemic sclerosis and in control groups of healthy subjects or in patients with other rheumatic disorders. These trials showed various proportions of systemic sclerosis patients with decreased bone mineral density in the range of 32 to 77%. Osteoporosis was found in 22 to 60% women with systemic sclerosis which was significantly more frequent that in healthy age-matched women (from 8 to 23%). The rates of osteoporotic fractures in patients with systemic sclerosis, according to data given by various authors, were in the range of 2 to 38%, being higher than in healthy controls (from 2 to 10%). In the majority of publications, there was an association of osteoporosis with conventional risk factors, and in some studies there was an association of osteoporosis with clinical characteristics of systemic sclerosis. The studies were performed in relatively small patient groups and their results vary widely. Further studies are necessary to elucidate the mechanisms of osteoporosis and improve its treatment and prevention in patients with systemic sclerosis